Skip to content

Randomized Clinical Trial, Conventional Treatment-controlled, Studying the Efficacy of Plasma Rich in Growth Factor (PRGF®) in Alveolar Ridge Preservation After Simple Exodontia in the Anterior Region of Maxilla.

Randomized Clinical Trial, Conventional Treatment-controlled, Studying the Efficacy of Plasma Rich in Growth Factor (PRGF®) in Alveolar Ridge Preservation After Simple Exodontia in the Anterior Region of Maxilla.

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04093583
Enrollment
46
Registered
2019-09-18
Start date
2019-11-07
Completion date
2025-01-29
Last updated
2025-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental Implantation

Keywords

exodontia, PRGF, alveolar ridge preservation

Brief summary

This RCT aims to study the efficacy and safety of PRGF-Endoret in alveolar ridge preservation in the aesthetic zone. The control group is the spontaneous healing occuring after the suturing of the alveolus. The primary endpoint is the bone regeneration measured in biopsies obtained from the regenerated alveolar bone.

Interventions

PROCEDUREExodontia

Atraumatic exodontia followed by simple suture

Filling of the alveolus with PRGF clot and fibrin plug.

DEVICEPreparation of PRGF using Endoret technology

Preparation of PRGF using Endoret technology following manufacturer instructions

Sponsors

Fundación Eduardo Anitua
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* \- Subjects of both sexes with an age greater than or equal to 18 years. * Clinical indication for a simple exodontia in the aesthetic zone (from left 2nd premolar to the right 2nd premolar in the maxilla). * Need of a dental implant placement in the extraction site. * Availability to follow-up during the treatment period * Subjects with non-active periodontal disease. * Buccal dehiscence \< than 25% in the vestibular table

Exclusion criteria

* \- Presence of an active infection * Loss of any plate of the socket * Severe inflammation in the area of the exodontia previous to the intervention * Have previous diagnosis of a coagulopathy. * Have previous diagnosis of any autoinmune disease. * Have received radiotherapy, chemotherapy or immunosuppressive treatments, systemic corticosteroids and/or anticoagulants the 30 days prior to inclusion * Regular treatment with AINES or other antiinflammatory drugs * Previous history of chronic hepatitis or heatic cirrhosis * Positive markers for VHC, AgHBs, VIH I/II or Treponema pallidum * Uncontrolled diabetes mellitus (Glycosylated hemoglobin higher than 9%) * Subjects submitted to hemodyalisis * Presence of malignant tumour, haemangiomas or angioma in the exodontia region. * Previous history of ischemic cardiopathy in the last year. * Pregnancy or womens in childbearing age who do not take contraception measures. * Nursing womens * Metabolic bone disease * Ongoing treatment with biphosphonates both through oral or intravenous administration * Smoking habits (\> 10 cigarrettes/day) * In general, any disability to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Bone regeneration12 monthsQuantity of new bone measured in bone biopsies obtained after alveolar ridge preservation

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026